Foundation Dutch Uro-Oncology Studygroup (DUOS)
Foundation Dutch Uro-Oncology Study group (DUOS) is a multidisciplinary study group comprising 27 academic and regional hospitals in the Netherlands. Our key interest is initiating and collaborating in investigator as well as Industry initiated and sponsored clinical trials in urological cancers. The spectrum includes the entire range of metastatic and non-metastatic and phase 1-3 clinical trials as well as post-marketing (phase 4) health- economics studies. DUOS collaborates with other national groups, such as the Scandic Group, the Spanish Oncology Genitourinary Group (SOGUG), as well as the Prostate Cancer Clinical Trials Consortium in the United States.
In addition DUOS provides information on latest developments and ongoing research for health care professionals and patients. Study group members support patients seeking KOL second opinions. This may include enrollment of potential patients onto DUOS clinical research programs at one of the participating sites. The group has received financial launching support from the Dutch Cancer Society. The board currently comprises one urologist: Dr Robert van Soest (SFGV Rotterdam); one nuclear medicine physician prof. dr. Daniela Oprea (RadboudUMC); one radiotherapist: dr. Karel Hinnen (Amsterdam UMC); and two medical oncologists, prof. dr. Andre Bergman (Netherlands Cancer Institute, Amsterdam) and prof. dr. Ronald de Wit (ErasmusMC Cancer Institute, Rotterdam, founding Chairman of DUOS). DUOS is registered by the Netherlands Chamber of Commerce.
Keynote- 199 (pembrolizumab), DORA (docetaxel +/- Rad223), SPLASH (Lutetium-PSMA) are examples of recent DUOS prostate cancer Industry trials. Ongoing IST health economics studies are APA/ENZA short; a randomized trial testing ADT plus 1 year ARPI, vs the standard regimen (until progression) and DAROTAXEL; a randomized trial of docetaxel or cabazitaxel with darotaxel, vs doce or caba alone in patients who have previously been treated with an ARPI.
Keynote studies (45, 52, 361, 57 , 992 and 676); IMVigor and Checkmate trials and NIAGARA (neoadjuvant chemo +/- durvalumab) are examples of urothelial cancer Industry trials.
RESPONDER (pembro biomarker discov), CHASIT (chemo plus avelumab neoadjuvant) and AVE short (exploring shortened duration of avelumab maintenance treatment) are recent IST studies. Ongoing are always at least twenty bladder cancer and prostate cancer studies.
More information:
DUOS c/0 Prof Ronald de Wit
Dept. Of Medical Oncology
r.dewit[at]erasmusmc.nl
DUOS secretariat:
communicatie[at]stichtingduos.nl